Functional Microdomains in G-protein-coupled Receptors
THE CONSERVED ARGININE-CAGE MOTIF IN THE GONADOTROPIN-RELEASING HORMONE RECEPTOR*

Juan BallesterosDagger §, Smiljka Kitanovic§, Frank GuarnieriDagger par , Peter Davies**, Bernard J. Fromme**, Karel KonvickaDagger , Ling Chi, Robert P. Millar**, James S. Davidson**, Harel WeinsteinDagger , and Stuart C. SealfonDagger Dagger §§

From the Dagger  Department of Physiology and Biophysics,  Fishberg Research Center in Neurobiology, and Dagger Dagger  Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 and ** Department of Chemical Pathology, University of Cape Town, Observatory 7925, Cape Town, South Africa

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

An Arg present in the third transmembrane domain of all rhodopsin-like G-protein-coupled receptors is required for efficient signal transduction. Mutation of this Arg in the gonadotropin-releasing hormone receptor to Gln, His, or Lys abolished or severely impaired agonist-stimulated inositol phosphate generation, consistent with Arg having a role in receptor activation. To investigate the contribution of the surrounding structural domain in the actions of the conserved Arg, an integrated microdomain modeling and mutagenesis approach has been utilized. Two conserved residues that constrain the Arg side chain to a limited number of conformations have been identified. In the inactive wild-type receptor, the Arg side chain is proposed to form an ionic interaction with Asp3.49(138). Experimental results for the Asp3.49(138) right-arrow Asn mutant receptor show a modestly enhanced receptor efficiency, consistent with the hypothesis that weakening the Asp3.49(138)-Arg3.50(139) interaction by protonation of the Asp or by the mutation to Asn favors activation. With activation, the Asp3.49(138)-Arg3.50(139) ionic bond would break, and the unrestrained Arg would be prevented from orienting itself toward the water phase by a steric clash with Ile3.54(143). The mutation Ile3.54(143) right-arrow Ala, which eliminates this clash in simulations, causes a marked reduction in measured receptor signaling efficiency, implying that solvation of Arg3.50(139) prevents it from functioning in the activation of the receptor. These data are consistent with residues Asp3.49(138) and Ile3.54(143) forming a structural motif, which helps position Arg in its appropriate inactive and active receptor conformations.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The gonadotropin-releasing hormone (GnRH)1 receptor is a member of the rhodopsin-like G-protein-coupled receptor (GPCR) family (1, 2). These heptahelical proteins include the visual opsins and various receptors for neurotransmitters, peptides, and glycoproteins. Activation of these receptors by their diverse agonists is associated with conformational changes in the receptor that facilitate a signal-propagating interaction with G-proteins (3). These conformational changes can involve relative movement of helices, as reported for rhodopsin (4, 5) and/or rotation of the helices as found in a constitutively active adrenergic receptor (6).

Sequence alignment of GPCRs shows that certain amino acids are highly conserved at corresponding positions within the putative transmembrane domains (TMD) (7). Transitions among receptor conformations may reflect dynamic changes in side chain interactions within the receptor. Two of these conserved residues have been studied by reciprocal mutation in the GnRH and serotonin receptors, and the results suggest that the TMD 2 and 7 side chains have an interdependent role in receptor activation (8, 9). Most likely several other conserved side chains also interact to form the skeleton required for the conformational rearrangements that accompany the transition between inactive and active receptor states.

The elucidation of the intramolecular interactions and conformational changes underlying receptor activation is hindered by the absence of high resolution structural data for any GPCR. The available low resolution projection maps of rhodopsin do not allow inferences about specific side chain interactions (10, 11). A prevalent approach to investigate structure-function relations of GPCRs is to introduce structural perturbations via site-directed mutagenesis and to evaluate their effect on receptor phenotype in binding and signal transduction assays (12). However, determining the phenotype of mutant receptors does not lead to an unequivocal interpretation concerning the structural basis of that phenotype (13).

Molecular modeling has facilitated the integration of experimental observations and biophysical data into a mechanistic scheme for receptor structure and function (12, 14). Structural and functional details of ligand binding (15, 16) and receptor activation by agonist complexing (8, 17) and by constitutively activating mutations (18) have been simulated in such models. The receptor models can thus provide a rationalization of current experimental data within a structural framework in which to explore the mechanisms underlying the functional perturbations induced by activation. However, caveats concerning the computational approaches arise from the complexity of these structures and the relative paucity of pertinent experimental data at atomic detail. Not surprisingly, given a limited number of experimentally determined constraints, the proposed models may exhibit inconsistent interaction patterns. In addition, GPCR models usually are not studied in the appropriate aqueous/membrane interface environment, making it less likely that the key side chain interactions are modeled accurately, especially those involving side chains near or separated by this interface.

To overcome the limitations inherent in both site-directed mutagenesis and computational modeling, we have integrated mutational studies and the application of computational techniques to the study of structural motifs in the receptor that may constitute functional microdomains. The inferences from studies of these microdomains, whose proposed structure can be substantiated by experimental data, are then evaluated in the context of a whole receptor model. This approach facilitates the elucidation of a structural basis for the phenotypes induced by site-directed mutagenesis. The effect of mutations is tested first in the microdomain models and correlated with the functional effects of site-directed mutant receptors expressed in mammalian cells. Using this approach, we have recently mapped precise interactions in segments of the binding pocket of the serotonin 5HT2A receptor (19).

In the present report, we have applied this approach to study the interaction pattern of the conserved Arg in TMD 3 in the GnRH receptor. The conserved arginine Arg3.50 (see "Experimental Procedures" for locus numbering scheme) has been implicated in the activation of various GPCRs by mutagenesis studies (20, 21) and by computational modeling (21, 22). An understanding of the molecular basis for the functional role of this Arg requires identification of those residues whose specific interactions determine its orientation within the structure of the receptor. Given the great conformational flexibility of the Arg side chain, it is likely that such orienting residues would form a three-dimensional motif to which we refer as the arginine cage.

Specific partners for Arg3.50 have been proposed, such as the conserved Asp in TMD 2 (Asp2.50) (21, 22), based on the rationale of a similar conservation pattern and the need to neutralize a positive charge in a low dielectric environment. However, a complete exploration of the conformational space of Arg3.50 in the context of a full molecular model of the receptor is not attainable with present computational techniques, and several other candidate interacting residues can be proposed. In particular, analysis of the conservation pattern centered on Arg3.50 identifies highly conserved residues that could influence the conformation of Arg3.50. These residues form the consensus sequence (I/L)XXDRYXX(I/V) (Fig. 1). Arg3.50, Asp/Glu3.49, and Ile/Val3.54 are present in all cloned GPCRs belonging to the rhodopsin family, with the exception of the platelet-activating factor receptor, which has an asparagine residue at position 3.49 (23). In an alpha -helical environment, the conservation pattern described above forms an envelope of conserved residues surrounding Arg3.50, consisting in the GnRH receptor of Ile3.46(135), Asp3.49(138), and Ile3.54(143) (Fig. 2).


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 1.   The conservation pattern of the cytoplasmic side of TMD 3 is demonstrated in an alignment of several GPCRs.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 2.   Spatial proximity between the conserved Arg3.50(139)) and the conserved residues surrounding it in TMD 3. A, helical net of TMD 3 of the human GnRH receptor showing Arg3.50(139) surrounded by conserved residues. B, three-dimensional computational model of TMD 3 of the GnRH receptor showing the spatial proximity of the conserved residues surrounding the Arg residue.

To evaluate the role of these various conserved residues in caging the Arg3.50 side chain in the inactive and active forms of the receptor, we have performed a complete conformational exploration of TMD 3 using Monte Carlo simulations (15). The helical structure and the helix ends of TMD 3 have been experimentally substantiated by Cys scanning of the D2 receptor (24) and by spin-labeling studies of rhodopsin, in which the membrane/aqueous interface has been located between residues 3.52 and 3.53 (25). For the Monte Carlo simulations, a novel biphasic solvent model has been developed that reproduces the interface between the interior of a protein and a water environment.2 Using this Monte Carlo approach, the inferences about the possible caging interactions involving the conserved Arg have been tested by evaluating computationally the structural effects of mutations in this TMD 3 domain model and correlating these results with the functional effects of site-directed mutagenesis. These studies provide insight into the role of Arg3.50(139) in sustaining a pattern of interactions that may occur in the active and inactive forms of the receptor.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Residue Numbering Scheme-- The residues in TMDs are numbered relative to the most conserved residue contained in the helix, as explained previously (14). On the basis of this scheme, the most conserved residue in TMD 3, Arg-139, is designated with the index number 3.50 and is hence referred to throughout as Arg3.50(139); the identification of the preceding Asp is Asp3.49(138).

Computational Methods-- The segment of TMD 3 from Cys3.25 to Thr3.55 was modeled as an alpha -helix. These helix boundaries, predicted following methodology described elsewhere (14), are consistent with recent experimental results for other GPCRs (24, 25). The environment surrounding the Arg residue in TMD 3 has been investigated in rhodopsin and found to consist of two distinct phases: a water phase and a membrane-embedded helix (25). The environment of Arg3.50(139) in the helix was assumed to be similar to the environment of residues buried inside the protein interior, consonant with studies on the known structure of the photosynthetic reaction center (26), and has been modeled by a distance-dependent dielectric. To simulate the biphasic environment in our calculations, the novel mixed solvent model includes a water phase and a distance-dependent dielectric phase.2 The boundary between the two phases consists of a plane parallel to the membrane. TMD 3 was initially positioned perpendicular to the membrane plane at the midpoint between residues 3.52 and 3.53 following experimental observations (23) but was allowed to move ± 2.3 Å vertically in the direction normal to the membrane plane to prevent arbitrary effects arising from the initial positioning.

To explore the conformational space available for the cytoplasmic portion of helix 3, Monte Carlo simulations were performed by varying the torsional angles for residues Val3.44(133) to Thr3.55(144). The variation of backbone dihedral angles phi  and psi  were restrained to ± 20° from their initial values. Side chain dihedral angles were rotated freely. Extensive simulations are necessary to reach convergence of the resulting conformations described by the rotamers we analyzed (see below for a description of the four consecutive dihedral angles defining the rotamers). Thus, between 100 and 400 rounds of independent random simulations were performed for each TMD 3 construct. In each round, repeated runs of Monte Carlo-simulated annealing were performed from a starting temperature of T1 = 2070 K, with a cooling schedule of Tn + 1 = 0.9 × Tn and 10,000 steps per temperature to reach 310 K. Between 19 and 76 million conformations were thus sampled for each wild-type and mutant construct. Analysis of the resulting conformations was performed at T = 310 K and restricted to backbone conformations within ± 10° from their initial values to maintain an alpha -helical conformation.

The conformations of the side chains, in particular the Arg3.50(139) side chain, are defined by the corresponding dihedral angles chi 1, chi 2, chi 3, chi 4. These dihedral angles are classified according to three main rotamers: gauche plus (g+) centered on -60° (encompassing angle values between -120° and 0°), gauche minus (g-) centered on +60° (between 0° and 120°), and trans (t) centered on 180° (between 120° and -120°). Evaluation of the preferred conformations was performed by analyzing the populations of each side chain rotamer. The rotamer state of the Arg side chain is defined by the state of each one of its four dihedral angles, e.g. the propensity of each dihedral angle (chi 1, chi 2, chi 3, chi 4) to adopt the (g+, g-, t) configuration. There are 81 possible Arg side chain rotamers, which were grouped according to their spatial orientation toward specific residues in TMD 3. The spatial orientation of each Arg3.50(139) rotamer was inferred from the average values of each of the four dihedrals defining each rotamer.

The Arg-cage microdomain resulting from this conformational analysis was positioned in the context of a complete model of the transmembrane helix bundle of the GnRH receptor (9), constructed to follow the electron microscopy projection map of rhodopsin (10) using methodological steps and approaches described in detail elsewhere (14).

DNA Constructs and Transfection-- Procedures for site-directed mutagenesis of the GnRH receptor, subcloning of the receptor coding region into pcDNA1/Amp and transient receptor expression have been described previously (27). COS-1 cells transfected with plasmid DNA were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. One day after transfection, COS-1 cells were split from 100-mm plates into two 12-well plates for the functional assay or into two 24-well plates for the whole-cell binding assay. Mutations of Asp3.49(138) and Arg3.50(139) were done in the mouse GnRH receptor, whereas mutations of Ile3.46(135) and Ile3.54(143) were generated in the human GnRH receptor.

Binding and Functional Assays-- Binding of GnRH to the wild-type and mutant receptors was measured at 4 °C in a whole-cell agonist competition binding assay 72 h after transfection (13). 125I-GnRH-A ((des-Gly10, D-Ala6, GnRH-ethylamide) was used as the label and displaced by increasing concentrations of GnRH. The Kd for GnRH-A was estimated from homologous competition binding. The radioactivity bound to membranes or cells was counted in a gamma -counter, and the amount of protein per well was determined using the Lowry method (28). The phosphatidylinositol hydrolysis assay was performed as described earlier (27). The binding and concentration-response curves were fitted using Kaleidagraph software (27). Ki and Bmax values were determined by using the program LIGAND (29).

Receptor Efficiency-- We have developed an empirical representation for receptor efficiency (Q) using operational models of occupancy and response (see Equations 1 and 2),
[<UP>AR</UP>]/B<SUB><UP>max</UP></SUB>=1/(1+K<SUB>d</SUB>/[<UP>A</UP>]) (Eq. 1)
E/E<SUB><UP>max</UP></SUB>=1/(1+<UP>EC</UP><SUB>50</SUB>/[<UP>A</UP>]) (Eq. 2)
where [AR] represents the concentration of ligand-receptor complex, [A] is the concentration of free ligand, and Emax and Bmax represent the maximal response and maximal binding, respectively. Receptor efficiency (Q) represents the quantal functional response achieved per agonist-occupied receptor. To allow comparison of the various mutant receptors and to accommodate the influence of spare receptors on EC50 values (27), we define receptor efficiency as (see Equation 3),
Q=E/[<UP>AR</UP>] (Eq. 3)
E represents the functional response obtained at a concentration of occupied receptor [AR] in the presence of agonist concentration [A] corresponding to the EC50 value for that particular receptor and agonist. For the GnRH receptor constructs, the agonist utilized for calculating Q is GnRH. Substituting and solving for Q, where [A] = EC50, gives (see Equation 4)
Q=(1/2)×[(K<SUB>d</SUB>+<UP>EC</UP><SUB>50</SUB>)/<UP>EC</UP><SUB>50</SUB>]×(E<SUB><UP>max</UP></SUB>/B<SUB><UP>max</UP></SUB>) (Eq. 4)
In calculating Q, Ki has been used as an estimate of Kd. The receptor efficiency values obtained for the various receptor constructs are expressed relative to the wild-type receptor value.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Computational Simulations of TMD 3 Segment Surrounding Arg3.50(139)

The GPCRs demonstrate a pattern of conservation among several residues that are in spatial proximity to Arg3.50(139) when the cytoplasmic side of TMD 3 is modeled as a regular alpha -helix (see Fig. 2). These potential local sites of interaction for Arg3.50 include the large hydrophobic residue (Ile/Val/Leu) at position 3.46, the acidic residue at position 3.49, the Tyr (Ser in the GnRH receptor) at position 3.51, and the beta -branched large hydrophobic residue (Ile/Val) at position 3.54.

The interaction patterns and rotamer positioning of Arg3.50(139) with respect to these neighboring TMD 3 residues were explored with Monte Carlo simulations for the wild-type helix and for various mutant receptors. Many conformations of the flexible Arg side chain were not attainable due to steric clashes with the helix backbone. For example, all Arg rotamers whose chi 1 = g- are unpopulated because of a clash between the Arg gamma -methyl and the backbone carbonyl from the preceding turn of the helix (30).

The most striking observation to emerge from the simulations is the tendency for Arg3.50(159) to form an ionic bond with Asp3.49(138), as illustrated in Fig. 2B. Nearly half of the Arg3.50(139) rotamers observed were bound to this aspartic acid (Table I). As shown in Fig. 3, a variety of Arg conformations were identified that form the Arg-Asp interaction. Most other side chains remained in their original orientations throughout the simulations, consistent with their preferred rotamer populations in known alpha -helical structures. Ser and Thr residues were overwhelmingly (92-99% of rotamers) in the chi 1 = g+ conformation due to H-bonding to the backbone carbonyl of the preceding turn (30, 31). beta -Branched residues (Val, Ile, Thr), except Ile3.54(143), were constrained to one single chi 1 population (83-99% of rotamers) due to clashes with the helix backbone (30). The structural effects of several mutations of the residues surrounding Arg3.50(139) were studied computationally:

                              
View this table:
[in this window]
[in a new window]
 
Table I
Preferred conformations of the Arg3.50(139) side chain-based rotamer populations for the wild-type and Asp3.49(138)-modified receptor by mutation (Asp3.49(138) right-arrow Asn) or protonation (Asp3.49(138) right-arrow Asp-H)
Orientation indicates the side chain locus that is in proximity to the Arg3.50(139) head group. All listed values are expressed as the percentage of total rotamer populations observed for each construct. Only rotamer populations present at greater than 5% for at least one of the constructs are shown.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 3.   Wild-type R3.50(139) orientations. Three-dimensional model of TMD 3 of the GnRH receptor illustrating the preferred conformations of the Arg side chain (purple) in the wild-type construct. Conserved residues are highlighted by thicker bonds. Note that all populated rotamer conformations are oriented toward Asp3.49(138), driven by an ionic bond between Arg3.50(139) and Asp3.49(138).

Ile3.46(135)-- The side chain at this position is not as well conserved as the other residues surrounding Arg3.50. Although Ile is most commonly found at this site, Leu or Met also occur in different receptors. For the simulations, we substituted Ile3.46(135) with Ala, Val, and Leu to test 1) the functional relevance of the wild-type side chain (by substituting Ala), 2) the role of the beta -branched character of the residue (by substituting Val), and 3) the effect of the large hydrophobic side chain (by substituting Leu). Monte Carlo simulations of all three mutant constructs showed that the conformational preferences of the Arg side chain were similar to those found in the wild-type receptor. Therefore, according to our results, Ile3.46(135) does not modulate the orientation of Arg3.50(139).

Asp3.49(138)-- Monte Carlo simulations were performed for a mutation of the conserved acidic residue to Asn. By neutralizing the charge at this locus, this Asp3.49(138) right-arrow Asn mutant would weaken the ionic bond between Arg3.50(139) and Asp3.49(138) observed in simulations of the wild-type receptor. This mutation was found to significantly affect the conformational preferences of the Arg side chain (see Table I). In the Asp3.49(138) right-arrow Asn mutant, the Arg side chain rarely interacts with the 3.49 locus (3% of rotamers). Two new orientations appear populated, as shown in Fig. 4. 1) Arg3.50(139) is oriented toward positions 3.47-3.51 where it can H-bond to Ser3.47(136) and Ser3.51(140) (37% of rotamers). 2) Arg3.50(139) is oriented toward positions 3.53-3.54 where it can be solvated by water at the cytoplasmic boundaries. Because activation of rhodopsin has been shown to involve a proton uptake by Glu3.49 (32, 33), simulations were also performed for the protonated form of the aspartic acid, termed Asp3.49(138) right-arrow Asp-H. The results yielded a pattern of preferred conformations very similar to that of Asp3.49(138) right-arrow Asn (Table II).


View larger version (111K):
[in this window]
[in a new window]
 
Fig. 4.   Arg3.50(139) orientations in the D3.49(138)N mutant. Three-dimensional model of TMD 3 of the GnRH receptor illustrating the preferred conformations of the Arg side chain (purple) in the D3.49(138)N construct. Conserved residues are highlighted by thicker bonds. Note that all the populated rotamer conformations are oriented away from Asn3.49(138). Instead, Arg3.50(139) is oriented either toward Ser3.51(140)-Ser3.47(136) (37.1%), where it can H-bond to the Ser residues, or toward the cytoplasm at the level of Ile3.54(143)-Ala3.53(142) (29.4%), where it would be solvated.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Preferred conformations of the Arg3.50(139) side chain based on rotamer populations for the wild-type and Ile3.54(143) mutants to Ala, Leu, and Val
All listed values are expressed as the percentage of total rotamer populations observed for each construct. Only rotamer populations greater than 5% for at least one of the constructs are shown.

Ser3.51(140)-- A Tyr residue most commonly occurs at this position in other GPCRs. We tested the functional role of this residue with the mutant construct Ser3.51(140) right-arrow Ala. Hydrogen-bonding between Arg3.50(139) and Ser3.51(140) was observed in the Asp3.49(138) right-arrow Asn mutant receptor, but the mutation Ser3.51(140) right-arrow Ala did not change significantly the orientation of the Arg side chain relative to the wild-type construct (data not shown). Evidently, this H-bond is not energetically competitive with the ionic bond Arg3.50(139)-Asp3.49(138).

Ile3.54(143)-- Only Ile or Val residues appear in GPCR sequences at this position. Therefore, this locus always contains a bulky beta -branched, hydrophobic side chain. To test the structural implications of these properties, we substituted this residue by Val, Leu, and Ala. The Val side chain displays similar structural features as isoleucine, being hydrophobic, bulky, and beta -branched. Leu is hydrophobic and bulky but has a gamma -branched side chain. Ala is hydrophobic but neither bulky nor branched. Analysis of all rotamers populated over 5%, shown in Table II, indicates that the prevailing interaction for the wild-type receptor and the three mutants is still the ionic bond between Arg3.50(139) and Asp3.49(138) (65-80% of rotamers). Although maintaining the same interaction, the individual rotamer conformations preferred for this interaction vary among the mutants and with respect to the wild-type receptor (Table II). Of note, a novel orientation for the Arg side chain toward residues 3.53-3.54 appears significantly populated in the Ile3.54(143) right-arrow Ala mutant (14.3%) but not in the wild-type, Ile3.54(143) right-arrow Val, or Ile3.54(143) right-arrow Leu mutants. In the Ile 3.54(143) right-arrow Ala mutant, the Arg side chain can be positioned toward the aqueous cytoplasm, as illustrated in Fig. 5.


View larger version (103K):
[in this window]
[in a new window]
 
Fig. 5.   R3.50(139) orientations in the I3.54(143)A construct. Three-dimensional model of TMD 3 of the GnRH receptor illustrating the preferred conformations of the Arg side chain (purple) in the Ile3.54(143) right-arrow Ala construct. Conserved residues are highlighted by thicker bonds. Most of the populated rotamer conformations are oriented toward Asp3.49(138), as observed for the wild-type (Fig. 4), driven by an ionic bond between Arg3.50(139) and Asp3.49(138). However, in this construct, Arg3.50(139) is also significantly oriented toward Ala3.54(143) (12.7%), where it would be solvated in the aqueous cytoplasm.

Radioligand Binding and Agonist-stimulated Inositol Phosphate Accumulation by the Wild-type and Mutant Receptors-- To correlate the predicted local structural roles of the conserved TMD 3 residues with their effect on receptor function, constructs obtained from the mutation of Arg3.50(139) and its surrounding conserved residues (see Fig. 2) were tested for their effects on ligand binding and inositol phosphate accumulation (Table III). The mutation of the Asp3.49(138), Arg3.50(139), and Ser3.51(140) loci were carried out on the mouse GnRH receptor, whereas the Ile3.46(135) and Ile3.54(143) mutants were generated in the human GnRH receptor. Both human and mouse GnRH receptors have identical sequences in the TMD 3 segment studied. The amino acid substitutions were designed to test the side chain property conserved at each locus and/or a specific functional hypothesis derived from the modeling studies. The results of the radioligand binding and phosphatidylinositol assay and the relative coupling efficiencies of the various receptor constructs are summarized in Table III.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Binding and activation of wild-type and mutant GnRH receptors expressed in COS-1 cells
The Ki and Bmax values are obtained from competition binding assays (mean ± S.E. from 3-5 experiments). The Emax and EC50 values are obtained from the phosphatidylinositol hydrolysis experiments (mean ± S.E. from 3-5 experiments). Basal activity was unchanged for all constructs. The mutations of Asp3.49(138) and Arg3.50(139) were generated in the mouse (m) GnRH receptor, whereas the mutations of Ile3.54(143) and Ile3.46(135) were made in the human (h) GnRH receptor. u, undetectable.

Ile3.46(135)-- Removal of the Ile side chain by the Ile3.46(135) right-arrow Ala mutation abolished binding and activation. Substitution by another beta -branched residue Ile3.46(135) right-arrow Val also eliminated detectable ligand binding and signal transduction. In contrast, the Ile3.46(135) right-arrow Leu receptor manifested coupling comparable to that of the wild-type receptor. However, due to poor expression of the Ile3.46(135) right-arrow Leu receptor (13% of wild-type receptor Bmax), the calculated value for receptor efficiency for this mutant reveals a 5-fold increase above the value obtained for the wild-type receptor (Table III). The affinity of this mutant construct for GnRH is comparable to the wild-type receptor. The restricted pattern of amino acid substitutions that are functionally tolerated at the 3.46(135) position is most consistent with this site being involved in helix-helix packing (see "Discussion").

Asp3.49(138)-- The Asp3.49(138) right-arrow Ala mutant had no detectable agonist binding or activation and could not be evaluated. The more conservative mutation Asp3.49(138) right-arrow Asn behaved like wild type in terms of its Ki, EC50, and Emax values (Table III). However, the lower Bmax (56% relative to wild type) suggests that this construct has a modestly enhanced signaling efficiency.

Arg3.50(139)-- Mutations of Arg3.50(139) to His and Lys yielded constructs with no detectable binding or activation. The Arg3.50(139) right-arrow Gln mutant expressed well and had wild-type affinity for GnRH but was very poorly coupled (Table III).

Ser3.51(140)-- Consistent with the lack of structural effects observed with mutation of this locus in the computational simulations, the phenotype of the expressed Ser3.51(140) right-arrow Ala mutant receptor was similar to that of the wild-type receptor (data not shown). This finding is consistent with results reported previously (34).

Ile3.54(143)-- The effects of mutating this locus to Val, Leu, and Ala were examined. In comparison with the wild-type receptor, the affinity of GnRH was modestly decreased for the Ala-substituted receptor. The Ile3.54(143) right-arrow Ala receptor showed a marked reduction in signaling efficiency, whereas the substitutions with Leu or Val were well tolerated (Table III).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Arg3.50 is absolutely conserved in all GPCRs, and its substitution in various GPCRs severely affects signal transduction (20, 21). The pattern of conservation and the effects of mutations make it likely that this side chain serves a key role in conformational changes and interactions underlying receptor activation. The results obtained with mutation of this locus in the GnRH receptor support a crucial role for this Arg in receptor function. Among the mutant receptors studied, only the construct with a Gln substitution at this site shows any detectable signal transduction. Similar results obtained by mutating the Arg3.50 in the mouse GnRH receptor have been recently reported (34).

Oliveira et al. (22) proposed a mechanism for receptor activation in which the change in orientation of this Arg3.50 constitutes an Arg-switch leading to activation of GPCRs, a hypothesis recently expanded by a combination of mutagenesis and computational simulations on adrenergic receptors (21, 35). The present study has focused on the molecular details of the microdomains surrounding Arg3.50 by delineating the neighboring residues that interact with or restrict the positioning of the Arg side chain.

Computational simulations provided structural hypotheses for the phenotypes observed with mutagenesis experiments. When studied mutants display detectable binding and affinities for GnRH similar to that of the wild-type receptor, we assume that the overall structure of the receptor was not perturbed significantly by these mutations. Mutant receptors without detectable binding also did not show detectable GnRH-induced signal transduction, suggesting that either the folding or the intracellular processing of these receptors was disrupted. The role of all potential Arg-cage side chains studied will be discussed separately based on the results from the computational simulations and the measured properties of the mutant constructs.

Asp3.49(138)-- Computational experiments indicate that the propensity to form an ionic bond between Arg3.50(139) and Asp3.49(138) constrains the orientation of the Arg side chain. This constraint is relieved when the simulations are carried out for the Asp3.49(138) right-arrow Asn mutant or for a protonated Asp3.49(138). The results of mutagenesis in the GnRH receptor and in other receptors suggest that the interaction between Arg3.50 and Asp3.49 stabilizes the inactive receptor state. In the alpha -adrenergic receptor, the mutation Asp3.49 right-arrow Asn leads to constitutive activation of the receptor (21, 35). We find that mutation of Asp3.49 right-arrow Asn leads to a modest increase in the efficiency of GnRH receptor activation similar to the reported result of the Glu3.49 right-arrow Gln mutation in rhodopsin (33).

In rhodopsin, receptor activation is accompanied by the uptake of two protons at cytoplasmic sites (32). One site of uptake has been identified as Glu3.49, based on the lack of proton uptake by the Glu3.49 right-arrow Gln mutant (32). Thus neutralization of the 3.49 locus by either protonation or mutation favors the activated form of the receptor. To rationalize these results in the structural context of the proposed Arg3.50-Asp3.49 interaction, we performed the relevant computational experiment of protonating Asp3.49(138) in the GnRH receptor. In the Monte Carlo simulations, neutralization of the acidic group at position 3.49 either abolished (Asp3.49 right-arrow Asp) or dramatically decreased (Asp3.49 right-arrow Asp-H) the orientation of the Arg side chain toward the 3.49 locus (Table I). Based on these experimental and computational findings, we hypothesize that the conserved Arg side chain is held by Asp3.49(138) through an ionic bond in the inactive state of the receptor and that receptor activation involves the release of this constraint on the Arg3.50(139) side chain conformation, most likely by protonation of Asp3.49.

Ile3.54(143)-- This locus shows a 100% conservation profile as a beta -branched, bulky hydrophobic residue (Ile or Val). Experimentally, the Ile3.54(143) right-arrow Val and the Ile3.54(143) right-arrow Leu mutants were similar or more efficient than the wild-type receptor. The Ile 3.54(143) right-arrow Ala mutant was inefficient in mediating signal transduction and displayed a much lower receptor efficiency than the wild-type receptor. In simulations, the preferred orientations of the Arg side chain in the Ile 3.54(143) right-arrow Val and the Ile 3.54(143) right-arrow Leu mutants were similar to those observed in the wild-type receptor. However, in the Ile3.54(143) right-arrow Ala mutant, a new orientation of the Arg side chain was significantly populated (14.3%, Table II). Analysis of the new rotamer conformations that are populated after mutation of Ile 3.54(143) right-arrow Ala provides a rationale for the observed phenotype. The bulky side chain of an Ile, Leu, or Val residue at this position would clash with the Arg side chain when this adopts the rotamer (t, g-, t, g+), as shown in Fig. 6. In contrast, an Ala at this position lacking the bulky side chain would allow this unfavorable conformation of the Arg residue, as can be seen in Fig. 5. According to the membrane-water boundary determined experimentally for rhodopsin and located between residues 3.52 and 3.53, the (t, g-, t, g+) rotamer of the Arg would orient the charged guanidinium group toward the aqueous cytoplasm. The strong solvation of the charged Arg side chain would inhibit it from further participation in any intramolecular interactions. Consequently, the results suggest that the structural role of Ile3.54 is to restrict the positioning of Arg3.50 during receptor activation. In the absence of a bulky side chain at this position, the solvation of Arg3.50 in the cytoplasm may prevent it from forming the interactions most conducive to establishing an active receptor state.


View larger version (95K):
[in this window]
[in a new window]
 
Fig. 6.   Proposed role of I3.54(143) in caging Arg3.50(139) through a steric clash. Three-dimensional model of TMD 3 of the GnRH receptor where R3.50(139) attempts to adopt the (t, g-, t, g+) rotamer configuration oriented toward the C terminus or cytoplasmic boundary of TMD 3 but clashes with Ile3.54(143). Note that in this conformation Arg3.50(139) reaches the membrane-cytoplasm interface (white line), as determined for rhodopsin (25), and could thus become solvated.

Ile3.46(135)-- In the simulations, the wild-type receptor and Ile3.46(135) mutant constructs showed similar orientations of the Arg side chain and the surrounding residues. Mutagenesis experiments show that mutation of Ile3.46(135) to either Ala or Val is not tolerated, whereas substitution by Leu shows increased receptor efficiency as compared with the wild-type receptor. Both the lack of a local helix 3 effect of mutation of this locus in computational experiments and the highly restricted pattern of functionally tolerated mutations suggest that Ile3.46(135) does not form a part of the Arg-cage motif and may have a role in interhelical interactions not considered in this study.

Ser3.51(140)-- Although there is a possible H-bonding interaction between Arg3.50(139) and Ser3.51(140), the interaction energy is not competitive with the strong Arg3.50(139)-Asp3.49(138) interaction that predominates in the wild-type receptor. Removal of the H-bonding group of Ser3.51(140) by substitution to Ala produced no detectable alteration of the functional properties of the GnRH receptor (32), suggesting that Arg3.50(139) does not interact with this site or that the energetic contribution of such an interaction to the receptor activation mechanism is not significant.

Mechanistic Hypothesis for the Transition from an Inactive to an Active State of the Receptor-- The implications of the pattern of interactions (e.g. Arg3.50(139)-Asp3.49(138)) and preferred conformations of the Arg3.50(139) side chain derived from conformational analysis on TMD 3 alone were further analyzed in the context of a seven TMD model of the receptor. Because the strongest interaction of Arg3.50 is an ionic bond, we explored whether an alternative charge counterpart (Asp/Glu) could be found within other TMDs. The Asp or Glu residues present within the transmembrane domains of the GnRH receptor are shown schematically in Fig. 7. An acidic counterpart for the Arg would be expected to share its high degree of conservation and to reside at the cytoplasmic side of a TMD. However, the only conserved acidic group in the TMDs of the GnRH receptor is the Asp3.49(138) in the TMD 3 studied here. There are three nonconserved acidic residues present in the TMDs of the GnRH receptor at positions Glu2.53(90) and Asp2.61(98) in TMD 2 and Asp7.49(319) in TMD 7 (Fig. 7). An interaction of Arg3.50(139) with Glu2.53(90) or Asp2.61(98) is inconsistent with the geometrical constraints of an engineered Zn2+ binding site reported recently between TMD 2 and TMD 3 for the NK-1 receptor (36). Therefore these interaction possibilities were excluded. An interaction of Arg3.50(139) with the nonconserved Asp7.49(319) is possible in the complete model of the transmembrane portion of the GnRH receptor.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 7.   Schematic representation of the human GnRH receptor showing the position of Asp or Glu residues within the TMD (black circles), relative to Arg3.50 (black circle) and the Arg-cage residues studied (shaded). Modeling in three dimensions indicates that Arg3.50 cannot interact with Asp2.61 or Glu2.53 in TMD 2, based on inferences from an engineered zinc-binding site between TMD 2 and TMD 3 (positions 2.64 and 3.28) (34). Aspartic acids Asp3.49 and Asp7.49 are in position to interact with Arg3.50. Asn2.50 is emphasized because it is a conserved Asp residue in most GPCRs and is proposed to interact with Arg3.50 when Asp7.49 is replaced by an Asn in these receptors.

Notably, Asp7.49(319) forms part of a pair of conserved residues for which modeling and double mutant studies suggest an involvement in GPCR activation (8, 9). An unusual feature of the GnRH receptor is the presence of an Asn at position 2.50 in TMD 2 (Fig. 7) where nearly all other rhodopsin family GPCRs have an Asp. On the other hand, Asp7.49(319) in the GnRH receptor is an Asn in most GPCRs. This apparent interchange of conserved residues suggests that these residues may interact, a hypothesis supported by molecular modeling and double mutation studies of both the GnRH receptor (9) and the serotonin 5-HT2A receptor (8). These results imply that Asp7.49(319) in the GnRH receptor substitutes functionally for the conserved Asp normally found at the 2.50 locus in other GPCRs and is therefore a suitable charged counterpart for Arg3.50 in terms of their high conservation profile. We suggest that one function of Asp7.49 in the GnRH receptor is to interact with Arg3.50 in the active state of the receptor. Exploring this possibility in the context of a model of the GnRH receptor supports an interchangeable role of Asp7.49(319) and Asn2.50(87) in the interaction with the Arg residue in TMD 3, as shown in Fig. 8A. The Arg side chain is capable of extending from TMD 3 toward TMD 2 and TMD 7, where it can interact simultaneously with Asp7.49(319) and Asn2.50(87). We hypothesize that during receptor activation, Asp3.49 becomes protonated, and Asp7.49 substitutes for Asp3.49 in forming an ionic interaction with Arg3.50.


View larger version (89K):
[in this window]
[in a new window]
 
Fig. 8.   Three-dimensional model of TMDs 2, 3, and 7 of the GnRH receptor showing proposed interactions between Arg3.50(139) and the residues at positions 3.49-2.50-7.49. A, GnRH receptor. Arg3.50 interacts with Asp3.49 and the side chains of Asp7.49 and Asn2.50. B, 5-HT2A receptor. Arg3.50 interacts with Asp3.49 and the carbonyls of Asn7.49 and Asp2.50. Note that the set of interactions between the Arg residue and the TMD 2-TMD 7 loci in the GnRH receptor can be mimicked in the 5-HT2A receptor, despite the reciprocal arrangement of Asn and Asp at the 2.50 and 7.49 loci.

In most GPCRs, the active state interaction would occur with the Arg3.50-Asp2.50 bond as shown in Fig. 8B. Several models of GPCRs have proposed an interaction of Arg3.50 with the Asp2.50-Asn7.49 locus (33, 20) but associate this interaction with the inactive state of the receptor. However, our data and results from other GPCRs described below support the role of this interaction with the conserved Asp/Asn pair at the 2.50-7.49 loci in stabilizing the active, not the inactive, receptor conformation. Thus, such a hypothesis is consistent with the finding in many GPCRs that mutations eliminating the charged character of Asp2.50, which would be expected to destabilize the proposed active-state Arg-Asp interaction, either abolish or significantly decrease receptor activity (37). Furthermore, spectroscopic experiments in rhodopsin showing that Asp2.50 is more strongly H-bonded upon activation (38), are also consistent with the proposed interaction between Arg3.50 and Asp2.50 in the active state.

In summary, the experimental and computational results suggest that the orientation of the highly conserved Arg3.50(139) side chain is constrained in the inactive receptor state by an ionic interaction with the neighboring conserved residue Asp3.49(138). During activation, Asp3.49 becomes protonated, and the Arg side chain is released. The conserved bulky side chain of Ile3.54(143) modulates the positioning of the Arg side chain by keeping it away from the cytoplasmic aqueous medium and thereby promotes the interaction with Asp7.49 (Asp2.50 in other GPCRs) that characterizes the active state of the receptor. Further studies of other structural motifs that have the role of functional microdomains will allow refinement of these proposed molecular events underlying receptor activation.

    ACKNOWLEDGEMENT

We thank Dr. Colleen Flanagan for critical reading of the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants RO1 DK46943, 5T32DA07135, and KO5 DA00060.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ The first two authors contributed equally to this work.

par Present address: Sarnoff Corp., 201 Washington Rd., Princeton, NJ 08543.

§§ Fishberg Center for Neurobiology Research, Box 1065, Mount Sinai School of Medicine, One Gustave Levy Place New York, NY 10029. Tel.: 212-241-7075; Fax: 212-996-9785; E-mail: sealfon{at}msvax.mssm.edu.

1 The abbreviations used are: GnRH, gonadotropin-releasing hormone; GPCR, G-protein-coupled receptor; TMD, transmembrane domain.

2 F. Guarnieri, manuscript in preparation.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Tsutsumi, M., Zhou, W., Millar, R. P., Mellon, P. L., Roberts, J. L., Flanagan, C. A., Dong, K., Gillo, B., and Sealfon, S. C. (1992) Mol. Endocrinol. 6, 1163-1169[Abstract]
  2. Chi, L., Zhou, W., Prikhozhan, A., Flanagan, C., Davidson, J. S., Golembo, M., Illing, N., Millar, R. P., and Sealfon, S. C. (1993) Mol. Cell. Endocrinol. 91, 1-6[CrossRef][Medline] [Order article via Infotrieve]
  3. Gudermann, T., Schoneberg, T., and Schultz, G. (1997) Annu. Rev. Neurosci. 20, 399-427[CrossRef][Medline] [Order article via Infotrieve]
  4. Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., and Khorana, H. G. (1996) Science 274, 768-770[Abstract/Free Full Text]
  5. Sheikh, S. P., Zvyaga, T. A., Lichtarge, O., Sakmar, T. P., and Bourne, H. R. (1996) Nature 383, 347-350[CrossRef][Medline] [Order article via Infotrieve]
  6. Javitch, J. A., Fu, D., Liapakis, G., and Chen, J. (1997) J. Biol. Chem. 272, 18546-18549[Abstract/Free Full Text]
  7. Probst, W. C., Snyder, L. A., Schuster, D. I., Brosius, J., and Sealfon, S. C. (1992) DNA Cell Biol. 11, 1-20[Medline] [Order article via Infotrieve]
  8. Sealfon, S. C., Chi, L., Ebersole, B. J., Rodic, V., Zhang, D., Ballesteros, J. A., and Weinstein, H. (1995) J. Biol. Chem. 270, 16683-16688[Abstract/Free Full Text]
  9. Zhou, W., Flanagan, C., Ballesteros, J. A., Konvicka, K., Davidson, J. S., Weinstein, H., Millar, R. P., and Sealfon, S. C. (1994) Mol. Pharmacol. 45, 165-170[Abstract]
  10. Schertler, G. F., Villa, C., and Henderson, R. (1993) Nature 362, 770-772[CrossRef][Medline] [Order article via Infotrieve]
  11. Schertler, G. F., and Hargrave, P. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11578-11582[Abstract]
  12. Baldwin, J. M. (1994) Curr. Opin. Cell Biol. 6, 180-190[Medline] [Order article via Infotrieve]
  13. Sealfon, S. C., Zhou, W., Almaula, N., and Rodic, V. (1996) Methods Neurosci. 29, 143-196
  14. Ballesteros, J. A., and Weinstein, H. (1995) Methods Neurosci. 25, 366-428
  15. Laakkonen, L. J., Guarnieri, F., Perlman, J. H., Gershengorn, M. C., and Osman, R. (1996) Biochemistry 35, 7651-7663[CrossRef][Medline] [Order article via Infotrieve]
  16. Almaula, N., Ebersole, B. J., Ballesteros, J. A., Weinstein, H., and Sealfon, S. C. (1996) Mol. Pharmacol. 50, 34-42[Abstract]
  17. Zhang, D., and Weinstein, H. (1993) J. Med. Chem. 36, 934-938[Medline] [Order article via Infotrieve]
  18. Scheer, A., and Cotecchia, S. (1997) J. Recept. Signal Transduct. Res. 17, 57-73[Medline] [Order article via Infotrieve]
  19. Almaula, N., Ebersole, B. J., Zhang, D., Weinstein, H., and Sealfon, S. C. (1996) J. Biol. Chem. 271, 14672-14675[Abstract/Free Full Text]
  20. Min, K. C., Zvyaga, T. A., Cypess, A. M., and Sakmar, T. P. (1993) J. Biol. Chem. 268, 9400-9404[Abstract/Free Full Text]
  21. Scheer, A., Fanelli, F., Costa, T., De Benedetti, P. G., and Cotecchia, S. (1996) EMBO J. 15, 3566-3578[Abstract]
  22. Oliveira, L., Paiva, A. C. M., Sander, C., and Vriend, G. (1994) Trends Biochem. Sci. 15, 170-172[CrossRef]
  23. Honda, Z., Nakamura, M., Miki, I., Minami, M., Watanabe, T., Seyama, Y., Okado, H., Toh, H., Ito, K., Miyamoto, T., and Shimizu, T. (1991) Nature 349, 342-346[CrossRef][Medline] [Order article via Infotrieve]
  24. Javitch, J. A., Fu, D., Chen, J., and Karlin, A. (1995) Neuron 14, 825-831[Medline] [Order article via Infotrieve]
  25. Farahbakhsh, Z. T., Ridge, K. D., Khorana, H. G., and Hubbell, W. L. (1995) Biochemistry 34, 8812-8819[Medline] [Order article via Infotrieve]
  26. Rees, D. C., Komiya, H., Yeates, T. O., Allen, J. P., and Feher, G. (1989) Annu. Rev. Biochem. 58, 607-633[CrossRef][Medline] [Order article via Infotrieve]
  27. Zhou, W., Rodic, V., Kitanovic, S., Flanagan, C. A., Chi, L., Weinstein, H., Maayani, S., Millar, R. P., and Sealfon, S. C. (1995) J. Biol. Chem. 270, 18853-18857[Abstract/Free Full Text]
  28. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
  29. Munson, P. J., and Rodbard, D. (1980) Anal. Biochem. 107, 220-239[Medline] [Order article via Infotrieve]
  30. McGregor, M. J., Islam, S. A., and Sternberg, M. J. (1987) J. Mol. Biol. 198, 295-310[Medline] [Order article via Infotrieve]
  31. Gray, T. M., and Matthews, B. W. (1984) J. Mol. Biol. 175, 75-81[Medline] [Order article via Infotrieve]
  32. Arnis, S., Fahmy, K., Hofmann, K. P., and Sakmar, T. P. (1994) J. Biol. Chem. 269, 23879-23881[Abstract/Free Full Text]
  33. Cohen, G. B., Yang, T., Robinson, P. R., and Oprian, D. D. (1993) Biochemistry 32, 6111-6115[Medline] [Order article via Infotrieve]
  34. Arora, K. K., Cheng, Z., and Catt, K. J. (1997) Mol. Endocrinol. 11, 1203-1212[Abstract/Free Full Text]
  35. Scheer, A., Fanelli, F., Costa, T., De Benedetti, P. G., and Cotecchia, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 808-813[Abstract/Free Full Text]
  36. Elling, C. E., and Schwartz, T. W. (1996) EMBO J. 15, 6213-6219[Abstract]
  37. van Rhee, A. M., and Jacobson, K. A. (1996) Drug Dev. Res. 37, 1-38[CrossRef]
  38. Rath, P., DeCaluwe, L. L., Bovee-Geurts, P. H., DeGrip, W. J., and Rothschild, K. J. (1993) Biochemistry 32, 10277-10282[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.